Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | R38C |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | PIK3CA R38C lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R38C confers a gain of function to Pik3ca, as indicated by increased phosphorylation of downstream targets Akt, GSK3-beta, FoxO1, FoxO3a, and S6 in cell culture (PMID: 18829572) and demonstrates increased transformation ability in two different cell lines, as compared to wild-type Pik3ca (PMID: 29533785). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA R38C |
Transcript | NM_006218.4 |
gDNA | chr3:g.179198937C>T |
cDNA | c.112C>T |
Protein | p.R38C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006713658.4 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179198937C>T | c.112C>T | p.R38C | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA R38C | head and neck squamous cell carcinoma | sensitive | Sulindac | Preclinical - Pdx | Actionable | In a preclinical study, Clinoril (sulindac) treatment reduced tumor growth rate in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring PIK3CA mutations, including PIK3CA R38C (PMID: 30683736). | 30683736 |